|
|
||||||||

*
Department of Medicine and Therapeutics, University of Aberdeen, Foresterhill, Aberdeen, United Kingdom; and
Institut National de la Santé et de la Recherche National, Unité 437, Nantes, France
Nephrotoxic nephritis (NTN) is characterized by acute
macrophage-dependent inflammation and serves as a model of human
glomerulonephritis. In this study we have transfected rat macrophages
with recombinant adenovirus expressing IL-4 (Ad-IL4) and demonstrated
that these transfected macrophages develop fixed properties as a result
of transfection, as shown by reduced NO production in response to
IFN-
and TNF. Ad-IL4-transfected macrophages localized with enhanced
efficiency to inflamed glomeruli after renal artery injection in rats
with NTN compared with adenovirus expressing
-galactosidase
(Ad-
gal)-transfected macrophages and produced elevated levels of the
cytokine in glomeruli in vivo for up to 4 days. The delivery of
IL-4-expressing macrophages produced a marked reduction in the severity
of albuminuria (day 2 albuminuria, 61 ± 15 mg/24 h) compared with
unmodified NTN (day 2 albuminuria, 286 ± 40 mg/24 h;
p < 0.01), and this was matched by a reduction in
the number of ED1-positive macrophages infiltrating the glomeruli.
Interestingly, the injection of IL-4-expressing macrophages into single
kidney produced a marked reduction in the numbers of ED1-positive
macrophages in the contralateral noninjected kidney, an effect that
could not be mimicked by systemic delivery of IL-4-expressing
macrophages. This implies that the presence of IL-4-expressing
macrophages in a single kidney can alter the systemic development of
the inflammatory response. Macrophage transfection and delivery provide
a valuable system to study and modulate inflammatory disease and
highlight the feasibility of macrophage-based gene
therapy.
This article has been cited by other articles:
![]() |
V. W. S. Lee, Y. M. Wang, Y. P. Wang, D. Zheng, T. Polhill, Q. Cao, H. Wu, I. E. Alexander, S. I. Alexander, and D. C. H. Harris Regulatory immune cells in kidney disease Am J Physiol Renal Physiol, August 1, 2008; 295(2): F335 - F342. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Wang, Y. Wang, Q. Cai, G. Zheng, V. W.S. Lee, D. Zheng, X. Li, T. K. Tan, and D. C.H. Harris By Homing to the Kidney, Activated Macrophages Potently Exacerbate Renal Injury Am. J. Pathol., June 1, 2008; 172(6): 1491 - 1499. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Liu, K. N. Stewart, E. Bishop, C. J. Marek, D. C. Kluth, A. J. Rees, and H. M. Wilson Unique Expression of Suppressor of Cytokine Signaling 3 Is Essential for Classical Macrophage Activation in Rodents In Vitro and In Vivo J. Immunol., May 1, 2008; 180(9): 6270 - 6278. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. M. Wilson, S. Chettibi, C. Jobin, D. Walbaum, A. J. Rees, and D. C. Kluth Inhibition of Macrophage Nuclear Factor-{kappa}B Leads to a Dominant Anti-Inflammatory Phenotype that Attenuates Glomerular Inflammation in Vivo Am. J. Pathol., July 1, 2005; 167(1): 27 - 37. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Ikezumi, L. Hurst, R. C. Atkins, and D. J. Nikolic-Paterson Macrophage-Mediated Renal Injury Is Dependent on Signaling via the JNK Pathway J. Am. Soc. Nephrol., July 1, 2004; 15(7): 1775 - 1784. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Satoh, T. Saika, S. Ebara, N. Kusaka, T. L. Timme, G. Yang, J. Wang, V. Mouraviev, G. Cao, E. M. A. Fattah, et al. Macrophages Transduced with an Adenoviral Vector Expressing Interleukin 12 Suppress Tumor Growth and Metastasis in a Preclinical Metastatic Prostate Cancer Model Cancer Res., November 15, 2003; 63(22): 7853 - 7860. [Abstract] [Full Text] [PDF] |
||||
![]() |
L.-P. Erwig, D. C. Kluth, and A. J. Rees Macrophage heterogeneity in renal inflammation Nephrol. Dial. Transplant., October 1, 2003; 18(10): 1962 - 1965. [Full Text] [PDF] |
||||
![]() |
B. Burke, S. Sumner, N. Maitland, and C. E. Lewis Macrophages in gene therapy: cellular delivery vehicles and in vivo targets J. Leukoc. Biol., September 1, 2002; 72(3): 417 - 428. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |